Lv11
90 积分 2021-05-26 加入
A tumor-conditional IL-15 safely synergizes with immunotherapy to enhance antitumor immune responses
2小时前
已完结
A survey of FDA Approved Monoclonal Antibodies and Fc-fusion Proteins for Manufacturing Changes and Comparability Assessment
2个月前
已完结
The present and future of bispecific antibodies for cancer therapy
8个月前
已完结
Antibody variable region engineering for improving cancer immunotherapy
2年前
已完结
An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity
2年前
已完结
Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity
3年前
已完结
Long-term outcome after allogeneic stem cell transplantation in multiple myeloma
3年前
已采纳
Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study
3年前
已采纳
皖公网安备34019202002308
